

Impact of Implementation Strategies on Lp(a) Testing in Secondary Care Settings

NCT07508007

Status RECRUITING
Sponsor Novartis Pharmaceuticals
Enrollment 4,500 participants

Key Eligibility Criteria

Inclusion (14)

- Lp(a) testing is available in this center and reimbursed.
 - Capacity to increase Lp(a) testing in relevant patient groups (according to the defined patient eligibility criteria).
 - Low and/or inconsistent Lp(a) testing rate(number of eligible patients tested for Lp(a)/number of eligible patients seen) <15%.
 - Willingness to fulfill research requirements, e.g., repurposing existing clinic data for research etc.
 - Seeing a defined number of eligible patients per year based on the sample size required for the study.
- ... and 9 more (see full listing online)

Exclusion (4)

- Centers with no access to Lp(a) testing.
- Centers where Lp(a) testing is not reimbursed.
- Electronic records will not be assessed for:
- \. Patients that have undergone Lp(a) testing prior to index date (for the post-index assessment)

Locations (1 total)

Novartis Investigative Site, Nuremberg, Germany